Email ID
Password
Scrip   
AstraZeneca withdraws US and EU filings for Zactima in lung cancer
28 October 2009
Malini Guha

AstraZeneca has withdrawn the US and EU filings of its most advanced anticancer in development, the oral multi-targeted kinase inhibitor Zactima (vandetanib) after regulators failed to be impressed by its efficacy. It had hoped the drug would secure approval as a second-line therapy in non-small cell...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36